Welcome to our dedicated page for Evaxion AS news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion AS stock.
Evaxion Biotech A/S (EVAX) is a clinical-stage biotechnology company leveraging proprietary AI platforms to advance immunotherapies for cancer and infectious diseases. This page serves as the definitive source for verified corporate announcements, research milestones, and strategic developments.
Investors and industry observers will find timely updates on clinical trial progress, regulatory filings, and technology innovations. Our curated collection includes press releases on AI-driven drug discovery, partnership announcements, and financial reports, all organized for efficient tracking of the company's trajectory.
Key content areas include updates from Evaxion's PIONEER and EDEN platform pipelines, oncology vaccine developments, and infectious disease research breakthroughs. The repository is maintained to reflect the company's evolving position at the intersection of artificial intelligence and immunotherapy.
Bookmark this page for streamlined access to Evaxion's official communications. Check regularly for new developments in personalized cancer vaccines and AI-optimized antigen discovery.
Evaxion Biotech A/S (NASDAQ: EVAX) has reported significant improvements in its AI-Immunology™ platform's predictive power for clinically relevant vaccine targets. In the ongoing phase 2 trial of their personalized cancer vaccine EVX-01, 79% of the AI-predicted vaccine targets triggered a tumor-specific immune response, up from 58% in the phase 1 trial.
This improvement is attributed to iterative learning and integration of advanced bioinformatics and machine learning techniques. The company believes this enhanced precision boosts the potential of its AI-derived vaccine candidates and is important for clinical efficacy and commercial potential.
CEO Christian Kanstrup emphasized the importance of this progress, stating that the 79% response rate compares favorably to other personalized cancer neoantigen trials. He also noted that the strong clinical outcome data provides Evaxion with a compelling AI-Immunology™ derived investigational vaccine candidate.
Evaxion Biotech A/S has expanded its collaboration with MSD through an option and license agreement for two preclinical vaccine candidates, EVX-B2 and EVX-B3. The deal includes:
- An upfront payment of $3.2 million
- Up to $10 million in 2025 if MSD exercises its option
- Potential milestone payments of up to $592 million per product
- Royalties on net sales
EVX-B2 targets Gonorrhea, while EVX-B3 targets an undisclosed infectious agent. This agreement validates Evaxion's AI-Immunology™ platform and aligns with their strategy of leveraging external collaborations. Evaxion will host a conference call on September 27, 2024, to discuss the agreement and recent company milestones.
Evaxion Biotech A/S (NASDAQ: EVAX) has launched an enhanced version of its AI-Immunology™ platform, featuring an updated EDEN™ AI prediction model. The new version 5.0 includes:
- A novel toxin antigen predictor
- An expanded training dataset
- Advanced protein feature prediction
These improvements are expected to accelerate vaccine development and strengthen Evaxion's position in AI-driven immunology. The platform can now deliver a new target within 24 hours, compared to years using traditional methods. The enhanced EDEN™ model's performance will be presented at the European Conference on Computational Biology in Turku, Finland.
Evaxion Biotech A/S (NASDAQ: EVAX) reports promising one-year data from its phase 2 trial of EVX-01, an AI-designed personalized cancer vaccine for advanced melanoma. Key findings include:
- 69% Overall Response Rate (11 out of 16 patients)
- Tumor reduction in 15 out of 16 patients
- 79% of vaccine targets triggered immune responses
- Positive correlation between AI-Immunology™ platform predictions and immune responses (p=0.00013)
The trial combines EVX-01 with MSD's KEYTRUDA® (pembrolizumab). These results validate Evaxion's AI-Immunology™ platform and position the company as a leader in AI immunology. With the global melanoma treatment market projected to reach $7.4 billion by 2029, EVX-01 shows significant commercial potential.
Evaxion Biotech A/S (NASDAQ: EVAX) has reported promising results from its phase 2 trial of EVX-01, its lead cancer vaccine candidate. The interim analysis shows a 69% Overall Response Rate, with 11 out of 16 patients experiencing objective clinical responses. Notably, 15 out of 16 patients showed tumor reduction. The trial combines EVX-01 with MSD's anti-PD-1 therapy, KEYTRUDA®, in advanced melanoma patients.
The complete one-year dataset will be presented at the ESMO Congress 2024 in Barcelona. Evaxion's CEO, Christian Kanstrup, expressed excitement about the data, emphasizing its support for EVX-01's clinical profile and the AI-Immunology™ platform's predictive capabilities. The company will host a webinar on September 18, 2024, featuring Professor Georgina V. Long to discuss the trial results and challenges in advanced melanoma treatment.
Evaxion Biotech A/S (NASDAQ: EVAX) has announced promising pre-clinical proof-of-concept data for its EVX-B2 mRNA Gonorrhea vaccine candidate. The data shows that the vaccine triggers a targeted immune response leading to the elimination of gonorrhea bacteria. This validates Evaxion's AI-Immunology™ platform as delivery modality agnostic, applicable across different vaccine modalities.
The results, presented at the 18th Vaccine Congress in Lisbon, demonstrate the potential of AI-Immunology™ in developing treatments for bacterial diseases. EVX-B2 was initially designed as a protein-based vaccine, and this new data for the mRNA version further substantiates the platform's versatility. The research was conducted in collaboration with Afrigen Biologics.
CEO Christian Kanstrup highlighted this milestone as part of Evaxion's 2024 strategy execution, emphasizing the platform's value proposition for partners. With no existing Gonorrhea vaccine, EVX-B2 represents a potentially groundbreaking treatment opportunity.
Evaxion Biotech A/S (NASDAQ: EVAX) has released its Q2 2024 financial results and business update. Key highlights include:
- Ongoing partnership discussions as part of multi-partner approach
- Positive Phase 2 immune data for EVX-01 presented at ASCO
- On track for Phase 2 one-year clinical data readout at ESMO Congress 2024
- Improved performance of AI-Immunology™ platform
- Cash position of $8.0 million as of June 30, 2024
- Net loss of $6.2 million for Q2 2024
The company expects its cash to fund operations into February 2025 but requires additional income or funding to continue as a going concern. Evaxion is working to regain Nasdaq compliance by November 4, 2024.
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio company specializing in AI-Immunology™ powered vaccines, has announced it will provide a business update and report second quarter 2024 financial results on August 14, 2024, before the Nasdaq-CM opens. The company's Executive Management will host a conference call and webcast at 14:30 CEST/08:30 EDT on the same day to present the update and results, as well as take questions. This event is free and open to the public. Interested parties can register in advance to receive dial-in details and a unique pin code for the conference call. A webcast link is also provided, and a recording will be available on Evaxion's website shortly after the event.
Evaxion Biotech A/S (NASDAQ: EVAX) will present one-year clinical efficacy data from its Phase 2 study on lead cancer vaccine candidate, EVX-01, at the ESMO Congress 2024 in September. EVX-01 is a personalized therapy for advanced melanoma, developed using Evaxion's AI-Immunology™ platform. The presentation, selected by the ESMO Congress Scientific Committee, will take place on September 14, 2024, in Barcelona, Spain.
CEO Christian Kanstrup emphasized the significance of this milestone, highlighting the opportunity to showcase their data to a global audience of experts and potential partners. The innovative approach aims to enhance treatment efficacy by targeting the unique genetic makeup of individual tumors.
Evaxion Biotech A/S (NASDAQ: EVAX) has unveiled improved performance of its key AI-Immunology™ building block, EvaxMHC, at the 32nd Intelligent Systems for Molecular Biology conference. The advancements in EvaxMHC are expected to enhance Evaxion's ability to accurately predict vaccine targets for personalized and precision vaccines in cancer and infectious diseases.
The improvements include:
- Utilization of a state-of-the-art deep-learning framework
- Creation of a unified representation for MHC class I and II molecules
- Implementation of a deep transformer encoder-decoder architecture
- Adoption of a generative adversarial network (GAN) pretraining mechanism
These enhancements have led to improved vaccine designs demonstrated in preclinical studies, particularly for MHC class II molecules, which have historically been challenging to predict accurately.
FAQ
What is the current stock price of Evaxion AS (EVAX)?
What is the market cap of Evaxion AS (EVAX)?
